150 related articles for article (PubMed ID: 30498011)
21. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
[TBL] [Abstract][Full Text] [Related]
22. The structural complexity of the human BORIS gene in gametogenesis and cancer.
Pugacheva EM; Suzuki T; Pack SD; Kosaka-Suzuki N; Yoon J; Vostrov AA; Barsov E; Strunnikov AV; Morse HC; Loukinov D; Lobanenkov V
PLoS One; 2010 Nov; 5(11):e13872. PubMed ID: 21079786
[TBL] [Abstract][Full Text] [Related]
23. BORIS in human cancers -- a review.
Martin-Kleiner I
Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
[TBL] [Abstract][Full Text] [Related]
24. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
Nguyen P; Cui H; Bisht KS; Sun L; Patel K; Lee RS; Kugoh H; Oshimura M; Feinberg AP; Gius D
Cancer Res; 2008 Jul; 68(14):5546-51. PubMed ID: 18632606
[TBL] [Abstract][Full Text] [Related]
25. DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation.
Sun L; Huang L; Nguyen P; Bisht KS; Bar-Sela G; Ho AS; Bradbury CM; Yu W; Cui H; Lee S; Trepel JB; Feinberg AP; Gius D
Cancer Res; 2008 Apr; 68(8):2726-35. PubMed ID: 18413740
[TBL] [Abstract][Full Text] [Related]
26. CTCF mediates chromatin looping via N-terminal domain-dependent cohesin retention.
Pugacheva EM; Kubo N; Loukinov D; Tajmul M; Kang S; Kovalchuk AL; Strunnikov AV; Zentner GE; Ren B; Lobanenkov VV
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2020-2031. PubMed ID: 31937660
[TBL] [Abstract][Full Text] [Related]
27. The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.
Zampieri M; Ciccarone F; Palermo R; Cialfi S; Passananti C; Chiaretti S; Nocchia D; Talora C; Screpanti I; Caiafa P
Biochim Biophys Acta; 2014 Sep; 1839(9):813-25. PubMed ID: 24984200
[TBL] [Abstract][Full Text] [Related]
28. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.
Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE
Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452
[TBL] [Abstract][Full Text] [Related]
29. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
[TBL] [Abstract][Full Text] [Related]
30. Widespread expression of BORIS/CTCFL in normal and cancer cells.
Jones TA; Ogunkolade BW; Szary J; Aarum J; Mumin MA; Patel S; Pieri CA; Sheer D
PLoS One; 2011; 6(7):e22399. PubMed ID: 21811597
[TBL] [Abstract][Full Text] [Related]
31. The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation.
Jelinic P; Stehle JC; Shaw P
PLoS Biol; 2006 Oct; 4(11):e355. PubMed ID: 17048991
[TBL] [Abstract][Full Text] [Related]
32. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
[TBL] [Abstract][Full Text] [Related]
33. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
[TBL] [Abstract][Full Text] [Related]
34. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
[TBL] [Abstract][Full Text] [Related]
35. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.
Bhan S; Negi SS; Shao C; Glazer CA; Chuang A; Gaykalova DA; Sun W; Sidransky D; Ha PK; Califano JA
Clin Cancer Res; 2011 Jul; 17(13):4267-76. PubMed ID: 21558405
[TBL] [Abstract][Full Text] [Related]
36. BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells.
Renaud S; Loukinov D; Alberti L; Vostrov A; Kwon YW; Bosman FT; Lobanenkov V; Benhattar J
Nucleic Acids Res; 2011 Feb; 39(3):862-73. PubMed ID: 20876690
[TBL] [Abstract][Full Text] [Related]
37. The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes.
Hore TA; Deakin JE; Marshall Graves JA
PLoS Genet; 2008 Aug; 4(8):e1000169. PubMed ID: 18769711
[TBL] [Abstract][Full Text] [Related]
38. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
Kang Y; Hong JA; Chen GA; Nguyen DM; Schrump DS
Oncogene; 2007 Jun; 26(30):4394-403. PubMed ID: 17260018
[TBL] [Abstract][Full Text] [Related]
39. A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
Yoon SL; Roh YG; Chu IS; Heo J; Kim SI; Chang H; Kang TH; Chung JW; Koh SS; Larionov V; Leem SH
Exp Mol Med; 2016 Jul; 48(7):e246. PubMed ID: 27416782
[TBL] [Abstract][Full Text] [Related]
40. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.
Jin W; Chen L; Chen Y; Xu SG; Di GH; Yin WJ; Wu J; Shao ZM
Breast Cancer Res Treat; 2010 Sep; 123(2):359-73. PubMed ID: 19943104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
